Find information on thousands of medical conditions and prescription drugs.

Creutzfeldt-Jakob disease

Creutzfeldt-Jakob Disease (CJD) is a very rare and incurable brain disease that is ultimately fatal. It is the most common of the transmissible spongiform encephalopathies (TSEs). It is a progressive neurological disorder which belongs to a group of degenerative neurologic diseases known as subacute spongiform encephalopathies. more...

Home
Diseases
A
B
C
Angioedema
C syndrome
Cacophobia
Café au lait spot
Calcinosis cutis
Calculi
Campylobacter
Canavan leukodystrophy
Cancer
Candidiasis
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Carcinophobia
Cardiac arrest
Cardiofaciocutaneous...
Cardiomyopathy
Cardiophobia
Cardiospasm
Carnitine transporter...
Carnitine-acylcarnitine...
Caroli disease
Carotenemia
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Causalgia
Cayler syndrome
CCHS
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Chalazion
Chancroid
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Chemodectoma
Cherubism
Chickenpox
Chikungunya
Childhood disintegrative...
Chionophobia
Chlamydia
Chlamydia trachomatis
Cholangiocarcinoma
Cholecystitis
Cholelithiasis
Cholera
Cholestasis
Cholesterol pneumonia
Chondrocalcinosis
Chondrodystrophy
Chondromalacia
Chondrosarcoma
Chorea (disease)
Chorea acanthocytosis
Choriocarcinoma
Chorioretinitis
Choroid plexus cyst
Christmas disease
Chromhidrosis
Chromophobia
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cinchonism
Citrullinemia
Cleft lip
Cleft palate
Climacophobia
Clinophobia
Cloacal exstrophy
Clubfoot
Cluster headache
Coccidioidomycosis
Cockayne's syndrome
Coffin-Lowry syndrome
Colitis
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conjunctivitis
Conn's syndrome
Constitutional growth delay
Conversion disorder
Coprophobia
Coproporhyria
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Costochondritis
Cowpox
Craniodiaphyseal dysplasia
Craniofacial dysostosis
Craniostenosis
Craniosynostosis
CREST syndrome
Cretinism
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Croup
Crouzon syndrome
Crouzonodermoskeletal...
Crow-Fukase syndrome
Cryoglobulinemia
Cryophobia
Cryptococcosis
Crystallophobia
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Cystinosis
Cystinuria
Cytomegalovirus
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Causes

TSEs (also known as prion diseases) are caused by a unique type of infectious agent called prions, an abnormally-structured form of a protein found in the brain. Other prion diseases include Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI) and kuru in humans, as well as BSE and scrapie in animals.

The prion that is believed to cause Creutzfeldt-Jakob exhibits at least two stable conformations. One, the native state, is water soluble and present in healthy cells. As of 2006, its biological function is unknown. The other conformational state is very poorly water-soluble and readily forms protein aggregates.

The CJD prion is dangerous because it promotes refolding of native proteins into the diseased state. The number of misfolded protein molecules will increase exponentially and the process leads to a large quantity of insoluble prions in affected cells. This mass of insoluble proteins disrupts cell function and causes cell death. Once the prion is transmitted, the defective proteins invade the brain and get produced in a self-sustaining feedback loop, causing exponential spread of the prion, and the patient dies within a few months; a few patients live as long as two years.

Incidence and prevalence

Although CJD is the most common human prion disease, it is still extremely rare and only occurs in about one out of every one million people. It usually affects people aged 45–75, most commonly appearing in people between the ages of 60–65. The exception to this is the more recently-recognised 'variant' CJD (vCJD), which occurs in younger people.

CDC monitors the occurrence of CJD in the United States through periodic reviews of national mortality data: According to the CDC:

  • CJD occurs worldwide at a rate of about 1 case per million population per year.
  • On the basis of mortality surveillance from 1979 to 1994, the annual incidence of CJD remained stable at approximately 1 case per million persons in the United States.
  • In the United States, CJD deaths among persons younger than 30 years of age are extremely rare (fewer than 5 deaths per billion per year).
  • The disease is found most frequently in patients 55–65 years of age, but cases can occur in persons older than 90 years and younger than 55 years of age.
  • In more than 85 percent of cases, the duration of CJD is less than 1 year (median: 4 months) after onset of symptoms.

Symptoms

The first symptom of CJD is rapidly progressive dementia, leading to memory loss, personality changes and hallucinations. This is accompanied by physical problems such as speech impairment, jerky movements (myoclonus), balance and coordination dysfunction (ataxia), changes in gait, rigid posture, and seizures. The duration of the disease varies greatly, but sporadic (non-inherited) CJD can be fatal within months or even weeks (Johnson, 1998). In most patients, these symptoms are followed by involuntary movements and the appearance of a typical diagnostic electroencephalogram tracing.

Read more at Wikipedia.org


[List your site here Free!]


Hearing loss as the initial presentation of Creutzfeldt-Jakob disease
From Ear, Nose & Throat Journal, 8/1/04 by Priya Krishna

Abstract

Creutzfeldt-Jakob disease is a rare type of spongiform encephalopathy. Affected patients present with constitutional symptoms, which progress to severe mental deterioration and movement disorders. Dizziness is the most common early otologic symptom. Few reports in the literature describe patients with Creutzfeldt-Jakob disease who present with sudden-onset hearing loss as their primary symptom for seeking treatment. This paper discusses one such patient and reviews the clinical presentation, treatment options, and relevant literature.

Introduction

Prion-associated encephalopathies are characterized by requiting a protein component (prion) for communicability. One such encephalopathy, Creutzfeldt-Jakob disease (CJD), has been recognized for more than a century. However, few reports in the literature describe patients who first present with otolaryngologic symptoms and signs. This prodromal complex may include symptoms such as dizziness or hearing loss in addition to the more commonly associated signs of progressive dementia, visual field defects, and ataxia. (1)

With this vague clinical picture, CJD can cause considerable diagnostic perplexity. In this article, we describe one patient with CJD who first presented with otolaryngologic symptoms and review the literature on this subject.

Case report

A 74-year-old woman presented to the otolaryngology clinic with a history of sudden-onset, right-sided hearing loss of 2 weeks' duration. Her history also included symptoms of sudden memory loss, ataxia, and diplopia. A poor historian, the patient was accompanied by a brother and sister who provided the history. Prior to her current illness, she lived independently. The patient's siblings were unaware of any history of vertigo or prior occurrence of similar symptoms. The patient developed progressive imbalance and had fallen three times in the 2 weeks prior to presentation. Her family also noted that she had scanning speech. The presumptive diagnosis after evaluation in a local urgent care department was Meniere's disease. The patient's past medical history was unremarkable except for abdominal lysis of adhesions and cataract surgery.

On physical examination, the patient exhibited poor eye tracking, shuffling gait, and truncal ataxia with intention tremor. Audiometric testing (figure 1) revealed moderate-to-severe bilateral sensorineural hearing loss with poorer word recognition than would be predicted by the degree of hearing loss.

[FIGURE 1 OMITTED]

The patient was admitted for further evaluation with a possible diagnosis of cerebrovascular accident. Several blood tests (erythrocyte sedimentation rate, angiotensin-converting enzyme I levels, Lyme titer, folate, vitamin [B.sub.12], ceruloplasmin, CSF analysis, thyroid panel, CHEM-7, and CBC) were ordered, all of which were negative or within normal limits. Magnetic resonance imaging of the brain (figure 2) indicated some periventricular white matter change; magnetic resonance angiography and carotid ultrasound were normal. In the first 2 weeks after her admission, the patient began to develop involuntary jerking of the upper extremities and increased tremor and startle myoclonus. Her symptoms continued to progress, and she developed aphasia and apraxia. An auditory brainstem response test was attempted, but waveforms were not reproducible. Electroencephalography was nonspecific, with background slowing and occasional triphasic waves (figure 3), indicating a global encephalopathy with lack of periodicity. A right frontal brain biopsy confirmed CJD by Western blot analysis with the presence of protease-resistant prion protein.

[FIGURES 2-3 OMITTED]

Following the initial workup, the patient was admitted to a rehabilitation unit to begin physical therapy. The patient's dementia and level of consciousness deteriorated rapidly, and she expired less than 2 months from her original date of admission.

Discussion

Creutzfeldt-Jakob disease is a rare disorder of transmissible spongiform encephalopathy characterized by progressive dementia. It is a prion disease requiring a protein component (prion) for transmissibility, similar to kuru, bovine spongiform encephalopathy (mad cow disease), and scrapie. Creutzfeldt and Jakob, independently, first described the disease. The first published description was of a 22-year-old woman with a 1-year history of progressive dementia, spasticity, ataxia, and startle myoclonus. (2) Simultaneously, Jakob identified 3 patients with a unique syndrome. (3-5) All were older than Creutzfeldt's patient and demonstrated a destructive process in the cerebral cortex, especially in the rolandic region, caudate, putamen, and thalamus. The first name for this disease was "spastic pseudosclerosis" because of its similarity to other diseases, such as multiple sclerosis and amyotrophic lateral sclerosis. A family with the disease was then described in the early to mid-1900s in which 11 members of the family had died of the same process. (6)

Multiple forms of CJD have been recognized. The first is the typical form, otherwise known as subacute spongiform encephalopathy. Variants are described on the basis of localization of the disease process and presenting symptoms. Familial fatal insomnia involves the thalamus, and Heidenhain's variant involves the occipital lobes. Related prion disorders include Gerstmann-Straussler-Scheinker syndrome, which is marked by cerebellar ataxia; and prion protein (PrP) and atypical forms of CJD caused by other mutations of the PrP gene (PRNP). (6)

The typical form of CJD has a mean age at onset of 60 [+ or -] 9 years. This is in contrast to Alzheimer's disease, the incidence of which increases markedly after age 60. There is no reported sex predilection for the disease. The annual incidence is 0.5 to 2 cases per million. (1,7) Approximately 15% of cases are familial, caused by a mutation on the gene encoding the PrP, and are transmitted in an autosomal dominant pattern. (6) Penetrance in familial cases also increases with age. Although 60% of familial mutations of the PRNP involve codon 200, multiple codons may be involved in members of the same family, as well as in variants of CJD. (6) Most cases are sporadic, but iatrogenic causes have been highly publicized. These include transmission via human cadaveric pituitary growth hormone, (8) corneal transplants, dural grafts, and EEG depth electrodes. (1) The iatrogenic cases involving pituitary hormone occurred in patients younger than 40 years of age, serving to differentiate them from sporadic cases. (8)

One third of patients experience prodromal constitutional symptoms, such as changes in sleeping and eating patterns and asthenia. Up to one fifth of the patients have a sudden onset of neurologic symptoms. (9) Dizziness is the most common otologic symptom noted. To date, only two other English-language reports of deafness as the primary presenting syndrome are published. (1,10) Tobias et al reported a patient with a progressive bilateral hearing loss that was cortical in origin, as indicated by phonologic errors consistent with abnormalities in central language processing. (10) In the second case, the patient presented with aural fullness and change in hearing. (1) Our patient had a progressive increase in baseline hearing loss with dysequilibrium but no vertigo. Patients with this constellation of symptoms may be diagnosed initially with a peripheral vestibulocochlear disorder, as in the case of our patient. Other early symptoms are visuospatial or cerebellar in origin, such as visual field defects, diplopia, and ataxia. (1,9)

Audiometric testing in these patients may reveal a poor word discrimination score that is out of proportion with the pure-tone hearing deficit. The role of imaging in the diagnosis of CJD is controversial. Computed tomography demonstrates volume loss in white matter and cortical atrophy with ventricular enlargement. In later stages of the disease, subdural fluid collections may be present. MRI, especially using higher-strength magnetic fields, may show high signals on T2 images in areas corresponding to the pathologic process, such as the basal ganglia, cortex, and periventricular white matter. Narrow-window techniques may increase the sensitivity for detecting early stages of CJD. (11) Single photon emission computed tomography (SPECT) has revealed cerebral perfusion deficits in CJD that may be used to differentiate it from other dementias, such as Alzheimer's disease. The correlation of SPECT scanning with the pathologic process behind CJD remains to be studied. (12)

CJD progresses relentlessly as patients develop further mental deterioration and movement disorders, such as chorea and myoclonus. Seizures may occur, and electroencephalographic testing is performed to assist in diagnosis. (9) More than 90% of patients in one series had findings of myoclonus, characteristic periodic sharp wave complexes (PSWCs), or both. (9) The accuracy of these PSWCs is debatable, with one series reporting a sensitivity of 67% and a somewhat higher specificity of 86%. Serial EEGs are recommended to help increase sensitivity. (13)

The ultimate diagnosis of CJD depends on neuropathologic findings in correlation with clinical history. A classic triad of spongiform change, neuronal loss, and astrocytosis has been well described (figure 4). However, spongiform change itself remains nonspecific; the only consistent location is in the head of the caudate nucleus. Spongiform change may also be absent in patients with a long duration of the disease. (14) PrP immunoreactivity may be performed for confirmation but may not distinguish typical CJD from clinical variants, (15) and only 10% of typical cases of CJD actually contain these PrP-positive amyloid plaques. (6)

[FIGURE 4 OMITTED]

CJD has a dismal outcome. Eighty percent of patients die within 1 year of onset, with the rest following a more chronic course. (6) Japanese forms of CJD have a much longer duration, with patients living beyond 4 years. (16) Little progress has been made in the search for treatment. Despite its rarity, it is important to be aware of this disease because of its significant diagnostic confusion.

References

(1.) Bigelow DC, Eisen MD, Yen DM, et al. Otolaryngological manifestations of Creutzfeldt-Jakob disease: Arch Otolaryngol Head Neck Surg 1998;124:707-10.

(2.) Creutzfeldt HG. Uber eine eigenartige herdformige Erkrankung des Zentralnervensystems. Vorlaufige Mitteilung. Zeitschrift fur die gesamte Neurologie und Psychiatrie 1920;57:1-18.

(3.) Jakob A. Uber eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischem Befunde (spastische Pseudosklerose-Encephalomyelopathie mit disseminierten Degenerationsherden). Vorlaufige Mitteilung. Deutsche Zeitschrift fur Nervenheilkunde 1921;70:132-46.

(4.) Jakob A. Uber eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischem Befunde (spastische Pseudosklerose-Encephalomyelopathie mit disseminierten Degenerationsherden). Zeitschrift fur die gesamte Neurologie und Psychiatrie 1921;64:147-228.

(5.) Jakob A. Uber eine der multiplen Sclerose klinisch nahestehende Erkrankung des Zentralnervensystems (spastische Pseudosklerose) mit bemerkenswertem anatomischem Befunde. Mitteilung eines vierten Falles. Med Klin 1921;17:372-6.

(6.) Richardson EP, Jr., Masters CL. The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of [PrP.sup.CID] in the nervous system. Brain Pathol 1995;5:33-41.

(7.) Manolidis LS, Balojannis SJ. Ultrastructural alterations of the vestibular nuclei in Jakob-Creutzfeld disease. Acta Otolaryngol 1983;95:508-21.

(8.) Brown P, Gajdusek DC, Gibbs CJ, Jr., Asher DM. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 1985;313:728-31.

(9.) Brown P, Cathala F, Castaigne P, Gajdusek DC. Creutzfeldt-Jakob disease: Clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986;20:597-602.

(10.) Tobias E, Mann C, Bone I, et al. A case of Creutzfeldt-Jakob disease presenting with cortical deafness (letter). J Neurol Neurosurg Psych 1994;57:872-3.

(11.) Garcia Santos JM, Lopez Corbalan JA, Martinez-Lage JF, Sicilia Guillen J. CT and MRI in iatrogenic and sporadic Creutzfeldt-Jakob Disease: As far as imaging perceives. Neuroradiology 1996;38: 226-31.

(12.) Aharon-Peretz J, Peretz A, Hemli JA, et al. SPECT diagnosis of Creutzfeld-Jacob disease. J Nucl Med 1995;36:616-17.

(13.) Steinhoff BJ, Racker S, Herrendorf G, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob Disease. Arch Neurol 1996;53:162-6.

(14.) Masters CL, Richardson EP, Jr. Subacute spongiform encephalopathy (Creutzfeldt-Jakob Disease). The nature and progression of spongiform change. Brain 1978;101:333-44.

(15.) Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 1995;5: 459-66.

(16.) Yagashita S, Iwabuchi K, Amano N, Yokoi S. Further observation of Japanese Creutzfeldt-Jacob disease with widespread amyloid plaques. J Neurol 1989;236:145-8.

From the Division of Otolaryngology, Southern Illinois University School of Medicine, Springfield.

Reprint requests: Priya Krishna, MD, Division of Otolaryngology, St. John's Pavilion, Mail Code 9662, 301 N. 8th Street, Springfield, IL 62794-9662. Phone: (217) 545-4777; fax: (217) 545-0253; e-mail: priyadonna@hotmail.com

COPYRIGHT 2004 Medquest Communications, LLC
COPYRIGHT 2004 Gale Group

Return to Creutzfeldt-Jakob disease
Home Contact Resources Exchange Links ebay